Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

5 marzo 2019 aggiornato da: Pfizer

A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C-PF-06700841] AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06700841 IN HEALTHY MALE SUBJECTS USING A 14C-MICROTRACER APPROACH

An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

6

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Olanda
      • Groningen, Olanda, 9728 NZ
        • PRA Health Sciences
      • Utrecht, Olanda, 3584 BL
        • PRA Health Sciences Utrecht

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Exclusion Criteria:

  • Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
  • Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
  • History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test
  • Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test
  • Use of herbal supplements within 28 days prior to the first dose of study medication
  • Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer
  • Inability to have at least one bowel movement every 2 days on average eGFR of <90 mL/mim/1.73 m2 based on MDRD equation
  • Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of investigational product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 2-period, fixed sequence
fixed sequence with 2 treatment period
Droga: Oral PF-06700841 containing 14C microtracer
Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
Droga: Oral unlabeled PF-06700841
60 mg unlabeled PF-06700841 oral dose in 2nd period
Droga: IV 14C-labeled PF-06700841
30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
mass balance_urine
Lasso di tempo: hour 0 up to 312 hours post dose
cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered
hour 0 up to 312 hours post dose
mass balance_feces
Lasso di tempo: hour 0 up to 312 hours post dose
cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered
hour 0 up to 312 hours post dose

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
metabolite identification_plasma
Lasso di tempo: hour 0 up to 312 hours post dose
metabolic identification and profiling in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma Cmax for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
maximum concentration of total 14C radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma Tmax for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
time with highest concentration of radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma AUClast for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
area under curve of total 14C radioactivity in plasma from time 0 to tlast following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma AUCinf for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
area under curve of total 14C radioactivity in plasma from time 0 to infinite following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
Oral clearance for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
oral clearance (CL/F) of total activity following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma half-life for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
half-life (t1/2) of total radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
volume of distribution for total 14C radioactivity
Lasso di tempo: hour 0 up to 312 hours post dose
apparent volume of distribution (Vz/F) of total radioactivity following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma Cmax for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
maximum concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma Tmax for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
time with highest concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUClast for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
area under curve of PF-06700841 in plasma from time 0 to tlast following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUCinf for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
area under curve of PF-06700841 in plasma from time 0 to infinite following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
Oral clearance for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
oral clearance (CL/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma half-life for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
half-life (t1/2) of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
volume of distribution for PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
apparent volume of distribution (Vz/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma Cmax for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
maximum concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma Tmax for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
time with highest concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUClast for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
area under curve of 14C-labeled PF-06700841 in plasma from time 0 to tlast following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUCinf for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
area under curve of 14C-PF-06700841 in plasma from time 0 to infinite following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
clearance for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
clearance (CL) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma half-life for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
half-life (t1/2) of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
volume of distribution for 14C-labeled PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
volume of distribution (Vz/F) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
unchanged PF-06700841 recovered in urine
Lasso di tempo: hour 0 up to 96 hours post dose
percentage of unchanged PF-06700841 recovered in urine (Ae%) following a single oral dose of PF-06700841
hour 0 up to 96 hours post dose
renal clearance of PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
renal clearance (CLr) following a single oral dose of PF-06700841 (Ae%/AUCinf for PF-06700841)
hour 0 up to 96 hours post dose
Bioavailability of oral PF-06700841
Lasso di tempo: hour 0 up to 96 hours post dose
Absolute bioavailability (F) following a single oral dose relative to a single iv dose of PF-06700841
hour 0 up to 96 hours post dose
Fraction absorbed of oral PF-06700841
Lasso di tempo: hour 0 up to 144 hours post dose
Fraction absorbed in gut (Fa) following oral dose of PF-06700841
hour 0 up to 144 hours post dose
metabolite identification_urine
Lasso di tempo: hour 0 up to 312 hours post dose
metabolic identification and profiling in urine following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
metabolite identification_feces
Lasso di tempo: hour 0 up to 312 hours post dose
metabolic identification and profiling in feces following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pfizer

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 dicembre 2018

Completamento primario (Effettivo)

21 febbraio 2019

Completamento dello studio (Effettivo)

21 febbraio 2019

Date di iscrizione allo studio

Primo inviato

6 dicembre 2018

Primo inviato che soddisfa i criteri di controllo qualità

6 dicembre 2018

Primo Inserito (Effettivo)

10 dicembre 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 marzo 2019

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 marzo 2019

Ultimo verificato

1 marzo 2019

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • B7931014
  • 2018-002403-34 (Numero EudraCT)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

No

Descrizione del piano IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Soggetti maschi sani

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Ukraine

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi